| __timestamp | ImmunityBio, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 2652041 |
| Thursday, January 1, 2015 | 226206000 | 2361587 |
| Friday, January 1, 2016 | 94391000 | 4472869 |
| Sunday, January 1, 2017 | 53821000 | 5030957 |
| Monday, January 1, 2018 | 35463000 | 4988941 |
| Tuesday, January 1, 2019 | 46456000 | 5196412 |
| Wednesday, January 1, 2020 | 71318000 | 6652774 |
| Friday, January 1, 2021 | 135256000 | 18418247 |
| Saturday, January 1, 2022 | 102708000 | 24827066 |
| Sunday, January 1, 2023 | 129620000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Opthea Limited and ImmunityBio, Inc. have taken different paths in this regard. From 2014 to 2023, ImmunityBio's SG&A expenses fluctuated significantly, peaking in 2015 with a staggering 2.26 billion, while Opthea maintained a more consistent approach, with expenses rising steadily to 41.9 million in 2023.
Opthea's strategy appears more stable, with a 58% increase in SG&A costs from 2021 to 2023, compared to ImmunityBio's 4% rise in the same period. This suggests Opthea's focus on gradual scaling, while ImmunityBio's expenses reflect a more volatile growth strategy. As we look to 2024, Opthea's data remains, but ImmunityBio's absence leaves questions about its future financial maneuvers.
Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Opthea Limited
AbbVie Inc. vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
BeiGene, Ltd. or Opthea Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Viatris Inc. and ImmunityBio, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
ImmunityBio, Inc. or Geron Corporation: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.